首页> 美国卫生研究院文献>other >Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake use and effectiveness in an open-label demonstration project in East Africa
【2h】

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake use and effectiveness in an open-label demonstration project in East Africa

机译:与艾滋病毒携带者伙伴一起对艾滋病毒阴性人群进行暴露前预防:东非一项开放性示范项目的吸收使用和有效性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Pre-exposure prophylaxis (PrEP) can provide high protection against HIV infection and is a recommended intervention for HIV-negative persons with substantial HIV risk.  Demonstration projects conducted in diverse settings worldwide illustrate practical examples of how PrEP can be delivered. This manuscript presents estimates of effectiveness and patterns of PrEP use within a two-year demonstration project of PrEP for HIV-negative members of heterosexual HIV serodiscordant couples in East Africa. >Methods: The PrEP delivery model integrated PrEP into HIV treatment services, prioritizing PrEP use for HIV-negative partners within serodiscordant couples before and during the first 6 months after the partner living with HIV initiated antiretroviral therapy (ART).  We measured PrEP uptake through pharmacy records and adherence to PrEP through medication event monitoring system (MEMS) bottle caps and quantification of tenofovir in plasma among a random sample of participants. We estimated HIV infections prevented using a counterfactual cohort simulated from the placebo arm of a previous PrEP clinical trial. >Results: We enrolled 1,010 HIV serodiscordant couples that were naïve to ART and PrEP.  Ninety-seven percent of HIV-negative partners initiated PrEP. Objective measures suggest high adherence: 71% of HIV-negative participants took ≥80% of expected doses, as recorded via MEMS, and 81% of plasma samples had tenofovir detected.  Four incident HIV infections were observed (incidence rate=0.24 per 100 person-years), a 95% reduction (95% CI 86-98%, p<0.0001) in HIV incidence, relative to estimated HIV incidence for the population in the absence of PrEP integrated into HIV treatment services.   >Conclusions: PrEP uptake and adherence were high and incident HIV was rare in this PrEP demonstration project for African HIV-negative individuals whose partners were known to be living with HIV.  Delivery of PrEP to HIV-negative partners within HIV serodiscordant couples was feasible and should be prioritized for wide-scale implementation.
机译:>背景:暴露前预防(PrEP)可以对艾滋病毒感染提供高度保护,是对具有大量HIV风险的HIV阴性人群的推荐干预措施。在全球范围内进行的示范项目展示了如何交付PrEP的实际例子。该手稿在为期两年的PrEP示范项目中为东非异性HIV血清型夫妻的HIV阴性成员提供了PrEP的有效性和使用方式的估算。 >方法:PrEP传递模型将PrEP整合到HIV治疗服务中,在患有艾滋病的伴侣开始抗逆转录病毒治疗(ART)之前和之后的头6个月内,优先为血清阴性夫妇中的HIV阴性伴侣使用PrEP 。我们通过药房记录测量了PrEP的摄入量,并通过药物事件监测系统(MEMS)瓶盖测量了PrEP的依从性,并从参与者的随机样本中定量了血浆中替诺福韦的含量。我们使用先前的PrEP临床试验的安慰剂组模拟的反事实队列评估了艾滋病毒感染的预防情况。 >结果:我们招募了1,010对天真的ART和PrEP未婚的HIV血清粘合剂。 97%的HIV阴性合作伙伴发起了PrEP。客观措施表明遵守率很高:通过MEMS记录,71%的HIV阴性参与者服用了≥80%的预期剂量,而81%的血浆样品中检测到替诺福韦。相对于没有艾滋病病毒感染者的估计艾滋病毒感染率,观察到四次艾滋病毒感染事件(每100人年= 0.24发生率),艾滋病毒发生率降低了95%(95%CI 86-98%,p <0.0001)。 PrEP已整合到HIV治疗服务中。 >结论:在这个PrEP示范项目中,PrEP的摄取率和依从性很高,而针对非洲HIV阴性个体(其伴侣已知感染HIV)的PrEP示范项目很少。向艾滋病毒血清伴侣中的艾滋病毒阴性伴侣提供PrEP是可行的,应优先考虑大规模实施。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号